



## Esophageal Cancer — Pathogenesis and Therapeutic Strategies

Guest Editors:

**Dr. I-Chen Wu**

Department of Medicine, College  
of Medicine, Kaohsiung Medical  
University, Kaohsiung, Taiwan

**Dr. Wen-Lun Wang**

Department of Digestive  
Endoscopy, E-Da Hospital/I-Shou  
University, Kaohsiung, Taiwan

**Dr. Wei-Lun Chang**

Department of Internal Medicine,  
National Cheng Kung University  
Hospital, Tainan, Taiwan

Deadline for manuscript  
submissions:

**closed (15 December 2022)**

### Message from the Guest Editors

Dear Colleagues,

Targeted therapies for esophageal cancer are important personalized treatments and may improve cancer outcomes. Previous studies and the genetic profiling of esophageal cancer have lead the treatment strategy from traditional chemoradiotherapy to immunotherapy. For poor responders to palliative chemotherapy, clinical trials on immune checkpoint inhibitors, targeting programmed death-1 (PD-1), PD-ligand 1 (PD-L1), or CTLA-4, have shown promising activity. Responders to immunotherapy may enjoy sustainable effects, but there is still no reliable biomarker to predict the response. Moreover, studies on esophageal carcinogenesis are ongoing, but the exact mechanisms behind it as well as the tumor microenvironment remain unclear.

In this Special Issue, we welcome original research and comprehensive review articles addressing the pathogenesis and potential targeted strategies of esophageal cancer to provide insights into clinical practice and future innovations. Researchers studying biomarkers, model systems, and preclinical or clinical trials using a targeted approach are invited to submit their work.

Dr. I-Chen Wu

Dr. Wen-Lun Wang

Dr. Wei-Lun Chang

*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)